Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Oct 18:19:1241-1244.
doi: 10.12659/AJCR.910224.

The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer

Affiliations
Case Reports

The Role of Immunotherapy and Radiation Therapy in Tumor Chemosensitivity in Advanced Head and Neck Cancer

Saad O Atiq et al. Am J Case Rep. .

Abstract

BACKGROUND Cancer is the second leading cause of death internationally, resulting in millions of deaths each year. While treatment in the past has heavily relied on surgery and radiotherapy, chemotherapy and immunotherapy are being increasingly utilized depending on disease presentation. CASE REPORT A 56-year-old male presented to the Emergency Department with a 3-week history of a rapidly enlarging left supraclavicular neck mass. Computed tomography scan revealed a 12×13 cm mass extending from the angle of the mandible to the supraclavicular area. A biopsy confirmed advanced stage squamous cell carcinoma of the head and neck. The patient was started on a chemotherapy regimen of docetaxel, cisplatin, and 5-fluorouracil (TCF). The tumor progressed through chemotherapy, which was switched to cetuximab; however, this therapy was discontinued after an anaphylactic reaction. Palliative radiation treatment was begun along with pembrolizumab. Pembrolizumab was continued, and after 9 cycles, the patient's cancer was almost in complete remission. Three months later, disease progression was once again noted with pembrolizumab treatment, which was subsequently discontinued. The patient was started on paclitaxel and carboplatin chemotherapy regimen as a last resort, despite failure of prior TCF treatment, and the patient responded, this time with complete remission in 4 months. CONCLUSIONS This case demonstrates a unique outcome in which a patient who previously was resistant to chemotherapy, later responded to chemotherapy after a trial of radiation therapy and immunotherapy. Immunotherapy may have a synergistic effect with radiation therapy and play a role in tumor sensitivity to chemotherapy in head and neck cancer treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1.
Figure 1.
Computed tomography image demonstrating progression with chemotherapy. Arrows denoting tumor borders.
Figure 2.
Figure 2.
Computed tomography image demonstrating remission after immunotherapy/radiation. Arrows denoting remaining tumor.
Figure 3.
Figure 3.
Computed tomography image demonstrating disease recurrence. Arrows denoting growing tumor.
Figure 4.
Figure 4.
Computed tomography image demonstrating complete remission with chemotherapy. Arrows denoting area previously occupied by tumor.

References

    1. Cancer [Internet] World Health Organization. World Health Organization; [cited 2018Jan22]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/
    1. Lefebvre J-L. Current clinical outcomes demand new treatment options for SCCHN. Ann Oncol. 2005;16:vi7–vi12. - PubMed
    1. Keir JA, Whiteside OJ, Winter SC, et al. Outcomes in squamous cell carcinoma with advanced neck disease. Ann R Coll Surg Engl. 2007;89:703–8. - PMC - PubMed
    1. Marur S, Forastiere AA. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501. - PubMed
    1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet. 2008;371:1695–709. - PMC - PubMed

Publication types

MeSH terms

Substances